Chapter 5 · The Landscape

Regulatory, Industry, Global & Cultural Landscape

FDA framework, CMS coverage, the UHMS, international practice variations across Russia, China, Japan, Israel, and Europe, the chamber-manufacturing industry, and the famous people and places of modern HBOT.

Chapter 5 of 6 · 68 cited sources · 6404 words
Download Full PDF (203 pages) All Chapters
Cited research, not medical advice. This is an educational compilation for reference and study. Prestige Hyperbaric is a wellness center, not a medical facility, and does not diagnose or treat any condition. The inclusion of a topic, study, or case does not constitute a recommendation. Always consult a qualified, licensed medical professional before considering hyperbaric therapy.

US Regulatory Framework

FDA Device Clearance Pathway (510(k))

Hyperbaric oxygen therapy chambers are classified as Class II medical devices and are cleared by the FDA through the 510(k) premarket notification process — not a full premarket approval (PMA). The relevant product code is CBF in the 510(k) database. Manufacturers must demonstrate that their chamber is substantially equivalent to a legally marketed predicate device. As the FDA confirms, clearance applies to the device, not to all possible clinical uses; using a cleared HBOT device for a non-cleared indication is considered off-label use.

A 2024 example from the FDA's own 510(k) database illustrates the typical indications language used in clearance submissions. The K240569 clearance for Fink Engineering's chambers lists the UHMS-recognized conditions verbatim as the approved indications:

"The conditions listed as appropriate for the use of HBO recognized by the Undersea & Hyperbaric Medical Society's (UHMS) Hyperbaric Oxygen Therapy Committee Report."

The 13 FDA-Cleared Indications (as stated by UHMS citing FDA, current as of 2024)

The FDA has cleared HBOT chambers for the following conditions. The UHMS, citing the FDA's own consumer communication, reproduces the FDA's language exactly:

1. Air and gas bubbles in blood vessels

2. Anemia (severe anemia when blood transfusions cannot be used)

3. Burns (severe and large burns treated at a specialized burn center)

4. Carbon monoxide poisoning

5. Crush injury

6. Decompression sickness (diving risk)

7. Gas gangrene

8. Hearing loss (complete hearing loss that occurs suddenly and without any known cause)

9. Infection of the skin and bone (severe)

10. Radiation injury

11. Skin graft or flap at risk of tissue death

12. Vision loss (when sudden and painless in one eye due to blockage of blood flow)

13. Wounds (non-healing, diabetic foot ulcers)

Note on count discrepancies: Various sources list 13, 14, or 15 indications depending on whether certain closely related conditions (e.g., CO poisoning and CO with cyanide; arterial insufficiency subcategories) are counted separately. The FDA's public-facing consumer language consolidates these into 13 grouped entries, while the UHMS Indications Manual formally enumerates 14 approved conditions (see UHMS section below), and Medicare covers 15 (see CMS section).

Conditions the FDA Explicitly States Are NOT Cleared

The UHMS-reprinted FDA statement directly quotes the agency:

"The FDA is aware there are some hyperbaric oxygen treatment centers promoting hyperbaric oxygen chambers for uses that have not been cleared or approved by the FDA, such as treatment of cancer, Lyme disease, autism, or Alzheimer's disease."

The FDA has also explicitly addressed COVID-19, issuing warnings during the pandemic that HBOT has not been cleared or approved for COVID-19 treatment. Direct-to-consumer wellness marketing for these conditions is a primary regulatory concern the FDA continues to monitor.

CMS / Medicare Coverage — National Coverage Determination (NCD 20.29)

The Centers for Medicare & Medicaid Services (CMS) covers HBOT under National Coverage Determination 20.29, which lists conditions for which Medicare Part B will pay for HBOT administered in a chamber (including a one-person unit).

The 15 Medicare-Covered Indications

As listed on the official Medicare.gov coverage page:

1. Acute carbon monoxide intoxication

2. Decompression illness

3. Gas embolism

4. Gas gangrene

5. Acute traumatic peripheral ischemia

6. Crush injuries and suturing of severed limbs

7. Progressive necrotizing infections

8. Acute peripheral arterial insufficiency

9. Preparation and preservation of compromised skin grafts

10. Chronic refractory osteomyelitis, unresponsive to conventional medical and surgical management

11. Osteoradionecrosis as an adjunct to conventional treatment

12. Soft tissue radionecrosis as an adjunct to conventional treatment

13. Cyanide poisoning

14. Actinomycosis, only as an adjunct to conventional therapy when the disease process is refractory to antibiotics and surgical treatment

15. Diabetic wounds of the lower extremities if: (a) the patient has Type 1 or Type 2 diabetes with a lower extremity wound due to diabetes; (b) the wound is classified as Wagner grade III or higher; and (c) the patient has failed an adequate course of standard wound therapy

Medicare cost-sharing: patients generally pay 20% of the Medicare-approved amount, and the Part B deductible may apply.

Local Coverage Determinations (LCDs): Individual Medicare Administrative Contractors (MACs) may issue LCDs that add documentation requirements, impose session limits (commonly 30–40 sessions for wound indications), or specify required pre-authorization steps. The NCD provides national baseline coverage while LCDs add local implementation detail.

State Licensing Variations

HBOT facility licensing varies considerably by state. Some states require facilities to operate under a physician's supervision; others have no specific HBOT regulations beyond general medical facility licensing. The proliferation of "wellness" soft-chamber studios in states with minimal oversight has drawn regulatory attention, as these facilities sometimes operate without physicians and market HBOT for non-cleared conditions. A handful of states (including Florida and Texas) have been particularly active markets for both medical and wellness HBOT.

Wound Care Center Accreditation

Two major accreditation frameworks govern hospital-based hyperbaric programs:

UHMS — Undersea and Hyperbaric Medical Society

History

The Undersea Medical Society (UMS) was founded on April 10, 1967 in Washington, D.C., by six U.S. Navy diving and submarine medical officers: Edward L. Beckman, Jack L. Kinsey, Christian J. Lambertsen (who wrote the Constitution), Walter F. Mazzone, Earl H. Ninow, and Robert D. Workman. The founding charter had 88 members, and the Aerospace Medical Association served as its initial institutional home.

As documented in the UHMS 15th Edition Indications manual front matter:

"In recognition of the dual interest by members in both diving and clinical applications of compression therapy, the society was renamed The Undersea and Hyperbaric Medical Society in 1986."

The name change reflected the rapidly growing interest in clinical hyperbaric oxygen therapy. By 1973, the UMS had grown enough to need a permanent office and hired Charles W. Shilling as its first executive secretary. The society's scientific journal, Undersea Biomedical Research, was established in 1974; in 1993, it merged with the Journal of Hyperbaric Medicine to become Undersea and Hyperbaric Medicine, still published today.

In 1972, an ad hoc Medicare committee was formed to evaluate HBOT's clinical efficacy for insurance coverage purposes. In 1976, the Hyperbaric Oxygen Therapy Committee became a standing committee, and the first Committee Report was published. Today the UHMS is headquartered at 631 US Highway 1, Suite 307, North Palm Beach, FL, and serves members from more than 67 countries.

The UHMS Indications Book

The UHMS Hyperbaric Oxygen Therapy Committee Report — colloquially known as the "Indications book" — is the authoritative scientific reference for HBOT indications globally. The 15th Edition is the current version (the previous 14th Edition had 14 approved indications; the 15th edition as cited in a 2024 PMC publication now lists 15). From the 28 indications recommended in the 1976 and 1979 reports, the committee refined the list down through decades of evidence review.

The 14 Approved UHMS Indications (as of the 14th Edition)

As listed on the UHMS official indications page:

1. Air or Gas Embolism

2a. Carbon Monoxide Poisoning

2b. Carbon Monoxide Poisoning Complicated by Cyanide Poisoning

3. Clostridial Myositis and Myonecrosis (Gas Gangrene)

4. Crush Injury, Compartment Syndrome, and Other Acute Traumatic Ischemias

5. Decompression Sickness

6a. Arterial Insufficiencies: Central Retinal Artery Occlusion

6b. Arterial Insufficiencies: Enhancement of Healing in Selected Problem Wounds

7. Severe Anemia

8. Intracranial Abscess

9. Necrotizing Soft Tissue Infections

10. Osteomyelitis (Refractory)

11. Delayed Radiation Injury (Soft Tissue and Bony Necrosis)

12. Compromised Grafts and Flaps

13. Acute Thermal Burn Injury

14. Idiopathic Sudden Sensorineural Hearing Loss — (New! Approved on October 8, 2011 by the UHMS Board of Directors)

The October 8, 2011 Addition of ISSHL

The addition of Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) as the 14th approved UHMS indication on October 8, 2011 represented the first new indication added in years and was significant because HBOT for sudden hearing loss had already been standard of care in Germany for decades. Substantial evidence, particularly from European studies, supported that HBOT combined with steroids was superior to steroids alone, especially when initiated within days of onset. Cochrane review evidence in 2025 confirms there is moderate evidence that HBOT improves hearing when applied up to 30 days after ISSHL onset.

UHMS Accreditation Program

The UHMS Facility Accreditation Program surveys hyperbaric facilities against detailed criteria. For facilities seeking "With Distinction" status, the UHMS With Distinction Guidance (2025) requires, among other things, that the Medical Director hold board certification in Undersea and Hyperbaric Medicine through ABEM, ABPM, or the Osteopathic Conjoint Committee, or completion of an ACGME-approved fellowship.

Annual Scientific Meeting (ASM)

The UHMS holds an Annual Scientific Meeting (ASM). The 2026 ASM is co-hosted with the Aerospace Medical Association (AsMA). Recent meetings have prominently featured data from the Multicenter Registry.

Multicenter Registry for Emerging Indications (Buckey, Dartmouth)

The Multicenter Registry for Hyperbaric Oxygen Therapy was initiated at Dartmouth-Hitchcock Medical Center and Elliott Hospital in 2011, under the direction of Dr. Jay Buckey of the Geisel School of Medicine, Dartmouth College. As of May 2024, 32 centers across the US, UK, and Australia are entering data, with a total of 9,019 cases in the registry. Of these, 378 cases were treated for non-UHMS-approved (emerging) indications. The registry uses REDCap with de-identified data. Notable emerging indications identified include inflammatory bowel disease (Crohn's and ulcerative colitis), where 47 UC and 40 Crohn's cases showed encouraging outcomes. Dr. Buckey delivered the Kindwall Keynote Lecture at the 2024 UHMS Annual Scientific Meeting in New Orleans on "New and Developing Indications for Hyperbaric Oxygen Treatment."

Global Approval Variations

Russia

Russia has one of the world's most extensive HBOT infrastructures. As documented at zavodmt.ru, over 1,200 HBOT providers operate in the country (one source cites 3,000 hyperbaric hospitals). Russia formally approves 71 indications for HBOT — far exceeding the FDA's list — reflecting the influence of academician B.V. Petrovski and the Russian Academy of Sciences in developing hyperbaric medicine as a mainstream therapeutic modality across virtually all fields of clinical practice. HBOT is integrated into military hospitals, sanatorium-spa institutions, and general clinical care. HBOT News catalogs a partial list of Russian-approved indications that include AIDS/HIV, Alzheimer's disease, autism, stroke, traumatic brain injury, cancer support, fibromyalgia, multiple sclerosis, and spinal cord injury — all considered off-label in the US.

China

China has the world's largest HBOT infrastructure by facility count. As reported in a 2015 PMC review of HBOT in China:

"Currently, there are more than 5,000 hyperbaric oxygen chambers in China. This number is the highest in the world."

The first hyperbaric chamber in China was used at the Fujian Medical University Union Hospital in 1964. The Chinese Medical Association (CMA) established a branch for hyperbaric oxygen medicine in 1992. The CMA issued its first indication standards in 1982 and revised them in 2004 and 2013. The 2004 standards listed 12 emergency indications and 48 non-emergency indications; the 2013 revision broadened the scope further. As of 2024, China formally recognizes approximately 65 indications, including stroke, traumatic brain injury, cerebral palsy, spinal cord injury, and peripheral neuropathy — conditions not covered in the US. Research quality has been a concern, with most Chinese clinical RCTs scoring low on quality scales due to small sample sizes and lack of blinding.

Japan

Japan's connection to HBOT runs deep. On November 9, 1963, a massive coal dust explosion at the Mitsui Miike Mikawa Coal Mine in Omuta, Kyushu, killed 458 workers and left 839 suffering acute carbon monoxide poisoning — the worst peacetime mine disaster in Japan's postwar history. The event, extensively documented in a 2023 PubMed study describing 33 years of follow-up, drove Japan's early adoption of HBOT for CO poisoning and established long-term post-CO syndrome as a distinct clinical entity. Japan currently recognizes approximately 20 approved HBOT indications as detailed by the Japan Society of Hyperbaric and Underwater Medicine, including cerebral infarction, head injury, spinal cord injury, and a unique indication for subacute myelo-optic neuropathy (SMON) — a condition of historic importance in Japan caused by the drug clioquinol. As cataloged in the Journal of Nippon Medical School (2025), Japan's indications also include compartment syndrome, intractable ulcers, and radiation injury.

Israel — The Sagol Center

Israel has become one of the world's leading centers for HBOT research and innovative clinical application, primarily through the work of Professor Shai Efrati and the Sagol Center for Hyperbaric Medicine and Research at Shamir (formerly Assaf Harofeh) Medical Center, Be'er Ya'akov. As described at shamir.org:

"The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center is the largest hyperbaric treatment center worldwide, treating more than 200 patients daily [and at peak periods up to 400 per day]."

Under Efrati's leadership since 2008, the Sagol Center has pioneered research into HBOT's effects on neuroplasticity, cellular aging, Alzheimer's disease, fibromyalgia, PTSD, long COVID, and post-stroke rehabilitation. A landmark 2020 study showed HBOT could increase telomere length and reduce senescent cells — the first therapeutic intervention proven to reverse these biological aging hallmarks. Israeli defense funding supports HBOT for combat veterans with PTSD; a 2024 randomized sham-controlled trial of 98 male IDF veterans with combat-associated PTSD found significant PTSD symptom improvement. The Sagol Center is affiliated with Aviv Clinics internationally, through which its protocols are commercialized globally.

Licensed and supervised HBOT centers in Israel, beyond the Sagol Center, include Tel Aviv Sourasky Medical Center, Hadassah-University Medical Center Jerusalem (Ein Kerem), and Elisha Hospital in Haifa.

United Kingdom / NHS

The UK's National Health Service (NHS) takes a conservative approach, specifying that HBOT is not routinely commissioned for several conditions that are covered in the US, including carbon monoxide poisoning, necrotizing soft tissue infections, soft tissue radiation damage from pelvic irradiation, and diabetic foot ulcers. NHS-commissioned indications align closely with the highest-evidence UHMS categories, particularly decompression illness and gas embolism. The British Hyperbaric Association (BHA) follows European Committee for Hyperbaric Medicine (ECHM) guidance and endorses HBOT for conditions including crush injury, DCS, radiation injury, osteomyelitis, and problem wound healing — but explicitly does not recommend "mild" HBOT (below 2.0 ATA). The DDRC Healthcare (Plymouth) and London facilities participate in the UHMS Multicenter Registry.

Germany

Germany is notable for having incorporated HBOT for idiopathic sudden sensorineural hearing loss (ISSHL) into standard clinical practice decades before the UHMS formally added it in 2011. German ENT guidelines have long supported HBOT as a first-line adjunct to corticosteroids for acute ISSHL, which is why the evidence base that eventually convinced UHMS was substantially European in origin. German hyperbaric medicine also maintains a robust acute care infrastructure and embraces radiation injury indications broadly.

Australia

Australia has well-established academic HBOT programs. The Prince of Wales Hospital Hyperbaric Unit (Sydney) — part of South Eastern Sydney Local Health District — treats diving-related injuries, soft tissue radiation injury, osteoradionecrosis, chronic non-healing wounds, necrotizing fasciitis, gas gangrene, sudden hearing loss, and CO poisoning, and celebrates 50 years of operation as of 2021. Alfred Health in Melbourne and additional centers participate in the UHMS Multicenter Registry. Australia's Medical Services Advisory Committee (MSAC) has conducted formal health technology assessments of HBOT, endorsing public funding for evidence-supported indications. The Royal Adelaide Hospital also maintains a significant program.

Emerging Markets: Mexico, India, Brazil

Brazil leads the Latin American HBOT market, with large hospitals using HBOT for diabetic wounds, infections, and sports injuries, supported by government wound care programs. India and Mexico are growing HBOT markets, driven by rising diabetes prevalence and medical tourism. As the global HBOT market research by Precedence Research documents, the global HBOT market was valued at approximately $3.98 billion in 2025 and is projected to reach $6.71 billion by 2034, with Asia Pacific growing at the fastest rate.

The Hyperbaric Industry

Major Chamber Manufacturers

Hard Chamber (Monoplace and Multiplace) — Major US and International Manufacturers:

Soft Chamber (Portable/Mild) Manufacturers:

Wound Care Chains

Hospital-based HBOT for wound care is dominated by a few large management companies that partner with hospitals to run hyperbaric programs:

Aviv Clinics — Premium HBOT Network

Aviv Clinics was founded based on the clinical protocols of Professor Shai Efrati and the Sagol Center. The current US facility is located at the Center for Advanced Healthcare at Brownwood in The Villages, Florida. Internationally, the affiliated Sagol Center in Israel operates 8 chambers treating 400 patients daily. Aviv has partnered with Koterra Health to offer PTSD/TBI treatment programs for veterans. The premium model positions HBOT alongside comprehensive cognitive and physical assessments, nutritional coaching, and structured exercise programs. A second facility was announced for Dubai. Aviv Clinics is UHMS-accredited, making it the first UHMS-accredited facility in the US primarily treating emerging indications.

Oxygen Sources / Concentrators

Medical HBOT programs use either bulk liquid oxygen (LOX) systems or high-pressure oxygen cylinder banks. For home soft-chamber use, consumers typically use oxygen concentrators delivering 87–96% oxygen. This distinction is clinically significant: UHMS defines HBOT as breathing ≥100% oxygen at >1.4 ATA; home concentrators paired with soft chambers delivering ambient air at 1.3 ATA do not technically meet this definition.

Hyperbaric Medicine as a Medical Specialty

ACGME Fellowship

Hyperbaric medicine training is formalized through ACGME-accredited fellowship programs in Undersea and Hyperbaric Medicine, typically lasting 12 months (one year). Graduates are eligible for subspecialty board certification. ACGME fellowship programs exist at academic medical centers including Dartmouth-Hitchcock, Duke, Long Beach Memorial, and others.

Board Certification

Two ABMS member boards certify physicians in Undersea and Hyperbaric Medicine:

Additionally, the UHMS offers a Certificate of Added Qualification (CAQ) in Undersea and Hyperbaric Medicine for physicians who may not meet the ABMS pathway requirements.

Scale of the Specialty

The number of UHMS board-certified physicians in the US is estimated at approximately 500–1,000 active diplomates. The number of hyperbaric treatment facilities in the US is estimated at over 1,500, including approximately 1,000 hospital-associated centers (each typically with 2–6 chambers) and a growing number of independent wellness and clinical facilities. One analysis cited in the Long COVID treatment paper estimates approximately 1,000 hospital-associated centers, each with an average of 4 chambers.

Famous Hyperbaric Facilities

HBOT Controversies & Debates

The Cunningham AMA Condemnation (1928)

Dr. Orval J. Cunningham (Kansas University, later Cleveland) is both a pioneering and cautionary figure in HBOT history. Beginning around 1918 during the influenza pandemic, Cunningham built progressively larger hyperbaric chambers, theorizing that diseases including cancer and diabetes were caused by anaerobic microorganisms that would be killed by pressurized oxygen. His backer, industrialist Henry H. Timken Jr., financed the construction of the "Timken Tank" (Cunningham's Spherical Sanitarium) in Cleveland — a five-story, 64-foot-diameter steel sphere weighing 900 tons, opened in 1928 at a cost of approximately $1 million ($15 million equivalent today). It contained 38 rooms with 350 portholes, a crystal chandelier recreation room, and an elevator.

As detailed by One Pager ICU's historical analysis and Time magazine (1942), the AMA investigated Cunningham's finances (finding he earned over $100,000/year — ~$1.4 million today) and invited him to publish his results. He was evasive. In May 1928, JAMA published a critical review finding no scientific basis for his claims. The combination of the Great Depression and AMA censure forced Cunningham to sell the sanitarium in 1934. It was repurposed as the Ohio Institute of Oxygen Therapy, which closed in 1936. In 1942, the US War Production Board ordered it scrapped for the war effort. A JAMA obituary noted the structure had "advanced a thesis that is altogether without scientific proof" and was "tinctured much more strongly with economics than with scientific medicine."

The Cunningham episode is frequently cited in HBOT debates to illustrate the risks of expanding HBOT indications without rigorous evidence — and equally, by HBOT advocates, to show how legitimate uses (CO poisoning, DCS) can be tarred by association with fringe claims.

The Autism HBOT Controversy (Rossignol 2009 RCT vs. Critics)

The most clinically contentious recent HBOT controversy involves its use in autism spectrum disorder (ASD). Dr. Daniel Rossignol published a hypothesis in 2006–2007 that ASD is characterized by cerebral hypoperfusion and neuroinflammation, and that HBOT's anti-inflammatory effects might improve symptoms. In 2009, Rossignol et al. published a multicenter, randomized, double-blind, controlled trial (BMC Pediatrics) enrolling 62 children with ASD aged 2–7 years across 6 centers. The treatment group (1.3 ATA, 24% oxygen, n=33) showed significant improvements compared to controls (1.03 ATA room air, n=29) in overall functioning, receptive language, social interaction, and eye contact on physician and parental CGI scales.

Critics raised several substantial objections: (1) The control condition (1.03 ATA, 21% O₂ — slightly pressurized room air) may not be an inert placebo, since even slight pressurization could have physiological effects; (2) 1.3 ATA with 24% oxygen does not technically meet the UHMS definition of HBOT (which requires ≥100% O₂ at ≥1.4 ATA); (3) improvements may reflect parental expectations rather than biological effect. The UHMS's own position paper on ASD acknowledged the Rossignol trial was the most methodologically rigorous available but questioned its control adequacy and urged further trials. A 2012 Cochrane-style review found the evidence inconclusive. The FDA and UHMS have not approved HBOT for autism, and the FDA explicitly names autism as a condition for which HBOT is being falsely marketed.

The Cerebral Palsy McGill 2001 Trial Controversy

The Collet et al. 2001 RCT (McGill University, published in The Lancet) enrolled 111 children with cerebral palsy (CP) aged 3–12 years, randomized to either HBOT (1.75 ATA, 100% O₂) or slightly pressurized room air (1.3 ATA). After 40 sessions, both groups improved on gross motor function, language, memory, and attention — with no statistically significant difference between them. The investigators concluded HBOT showed no benefit beyond the control condition.

The controversy ignited immediately. HBOT advocates argued the 1.3 ATA air control was itself a therapeutic intervention (not a true placebo), meaning both arms received forms of hyperbaric therapy. The Fonds de recherche en santé du Québec (FRSQ) issued a press release retitling the study "No Advantage of High-Pressure Oxygen for Treating Children with Cerebral Palsy," which critics called a misrepresentation of the published results. A 2022 systematic review in PMC concluded: "there is high-level evidence that HBOT does not improve motor function, cognition, and functional performance in children with CP" and that "HBOT is not recommended in clinical practice in children with CP" — effectively closing the debate.

TBI: Wolf 2012 vs. Harch 2012 — The "Dueling Trials"

The controversy over HBOT for mild traumatic brain injury (mTBI) / persistent post-concussion syndrome (PPCS) crystallized around two 2012 publications:

Wolf et al. (2012) — DoD-funded trial at San Antonio Military Medical Center (results published in Journal of Neurotrauma): 72 military service members with chronic mTBI randomized to HBOT at 2.4 ATA (90 min/session, 30 sessions) or "sham" (1.3 ATA room air). Conclusion: "HBO₂ at 2.4 ATA pressure had no effect on post-concussive symptoms after mild TBI" — both groups improved, with no between-group difference.

**Harch's rebuttal (published in Journal of Neurotrauma, 2013): Dr. Paul Harch argued that the Wolf study was not a sham-controlled trial but a comparative dose study** — the 1.3 ATA air control group was exposed to both increased pressure and slightly increased plasma oxygen, neither of which is inert. As Harch wrote: "pressurized air is biologically active...the Wolf 'sham' control group cannot test for placebo effects." Both groups showed significant PTSD and PCS symptom improvements; Harch interpreted this as evidence of efficacy at both doses.

This debate remains unresolved. A 2021 VA Evidence Synthesis Program report and a 2025 DoD Information Paper both concluded: "evidence from both military and civilian studies does not support using hyperbaric oxygen therapy to manage TBI" — and the 2021 VA/DoD clinical practice guideline recommends against HBOT for mTBI. HBOT is not VA-covered for TBI. Multiple state legislatures, meanwhile, have been introducing bills to fund HBOT pilots for veterans with PTSD/TBI (Iowa, Indiana, Kentucky, Missouri, North Dakota, New York, Oregon as of 2025).

"Mild HBOT" vs. Medical-Grade Debate

The proliferation of soft-shell portable chambers operating at 1.3 ATA with ambient air (or low-flow oxygen concentrators achieving ~24% O₂) has created a definitional battle. The UHMS explicitly states: "Hyperbaric treatment at minimally elevated chamber pressures (mild hyperbaric oxygen) is unproven. Mild hyperbaric oxygen therapy is currently considered to be exposures delivered at pressures lower than 1.5 ATA." The Sagol Center's Professor Efrati, despite being associated with commercial HBOT ventures, has dismissed soft chambers as "sacks full of air" and warned that wellness marketing misappropriates his research, which was conducted under rigorously controlled conditions using hard-shell chambers at 2.0 ATA with 100% oxygen. As the New York Times reported (2026), Efrati warned: "Using the term 'wellness' lends credibility to practices that lack evidence... Moreover, it can be hazardous."

Insurance Coverage Gaps and Patient Costs

With only ~14–15 covered indications and significant off-label demand, many patients face large out-of-pocket costs. The insurance battle is particularly acute for TBI, PTSD, long COVID, autism, and anti-aging uses. Patient advocacy groups, particularly for veterans, have pushed for legislative mandates for VA coverage.

Aviv Clinics Expansion Model (Premium Wellness HBOT)

Aviv Clinics has pioneered a "premium wellness" HBOT model targeting affluent clientele seeking cognitive enhancement, healthy aging, and neurological rehabilitation. Pricing is publicly listed: Performance Base program ($18,214 for 8 weeks), Enhancement Base ($29,546 for 12 weeks), Enhancement Premium ($48,596), Recovery Base ($33,846), and Recovery Premium programs. Programs include comprehensive pre/post assessments (MRI, SPECT imaging, cardiopulmonary exercise testing, cognitive batteries), and treatment combines HBOT with personalized physical training, cognitive training, and nutritional coaching. Dubai expansion was announced; the US flagship is in The Villages, Florida.

Athletic / Longevity / Biohacker Market

HBOT has become central to the longevity/biohacker ecosystem, featured prominently alongside cold plunge, red light therapy, and IV infusions. As NY Times and CB Insights coverage (2026) documents, HBOT chambers are being installed in luxury real estate "longevity rooms" in London, Los Angeles, and Dubai. Social wellness clubs like Remedy Place (New York) offer HBOT as part of membership programs. Biohackers and influencers have significantly driven consumer awareness.

Chamber-Share / Membership Clinics

A new business model of independent "chamber-share" clinics offers monthly memberships for ongoing HBOT access at effective per-session costs of $60–$150 — dramatically below hospital-based pricing. These clinics operate in the wellness space, often without physician oversight, raising quality and safety concerns.

Long COVID Specialty Centers

HBOT emerged as one of the most-discussed potential treatments for Long COVID. Israeli researchers from the Sagol Center published the first randomized controlled trial of HBOT for Long COVID in 2022 (Scientific Reports), showing significant improvements in cognitive function, fatigue, pain, and quality of life. As CNBC reported (2023), HBOT for Long COVID remains off-label and insurance-uncovered, forcing patients to pay out of pocket. An analysis by ESMED (2024) estimated it would take 500 years to treat all current US Long COVID patients using existing HBOT capacity — underscoring the massive unmet demand.

Veterans Affairs / HBOT for PTSD and TBI

Congressional pressure has intensified to expand VA HBOT access for combat veterans with PTSD and TBI. Multiple states passed or introduced legislation in 2025 funding HBOT pilots for veterans. A 2024 study (Sagol Center) found 68% of veterans with combat-associated PTSD showed significant PTSD improvement after 60 sessions, with 25% achieving complete remission. The VA/DoD official position remains against HBOT for TBI as of the 2021 clinical practice guideline, though multiple research trials continue. Congressman Greg Murphy (NC) introduced legislation in 2025 to offer HBOT to veterans.

Famous People Who Have Used HBOT

Joe Namath (TBI/Dementia)

Former New York Jets quarterback Joe Namath is HBOT's most prominent public advocate. Following SPECT brain scans showing significant TBI-related hypoperfusion from his football career, Namath underwent 120 sessions of HBOT at Jupiter Medical Center (Florida) from August 2012 to March 2013, at one hour per day, five days per week. Follow-up SPECT imaging reportedly showed normalization of the previously dark/hypoperfused areas. Namath subsequently launched the Joe Namath Neurological Research Center at Jupiter Medical Center to fund a clinical trial of HBOT in 100 subjects with symptoms of brain damage.

Michael Jackson (Oxygen Chamber Tabloid Story, 1986)

The most famous (and extensively misrepresented) celebrity HBOT story. In September 1986, photos appeared in the National Enquirer of Jackson reclining in a Sechrist 2500B hyperbaric chamber at the Brotman Medical Center in Culver City, California (which treated him after his 1984 Pepsi commercial burns). Tabloids claimed he slept in it nightly to live to 150. Time magazine reported the story in its September 29, 1986 issue. Jackson's own physician advised against the practice; Sechrist Industries founder J. Ronald Sechrist publicly stated the company had not sold a chamber to Jackson and would not do so. Jackson later bought the specific chamber from the hospital in 1994 (it is now owned by OxyHeal, a medical center). Jackson himself denied the tabloid story in a 1993 Oprah Winfrey interview. UPI documented the original story in 1986.

Justin Bieber

Bieber posted images of himself using a hyperbaric chamber on Instagram in 2019, citing it as helping with his stress, anxiety, ADHD, and Lyme disease. He reportedly has chambers in both his home and his recording studio. "Mental health is so important to get on top of," Bieber said from inside the chamber. His usage normalized HBOT among younger wellness demographics. Bieber's public Lyme disease diagnosis brought particular attention, as Lyme disease is one of the conditions the FDA explicitly names as not cleared for HBOT.

LeBron James

LeBron James has used HBOT for athletic recovery, reportedly maintaining a chamber at home. The increased oxygen delivery supports tissue regeneration, angiogenesis, fibroblastic proliferation, and collagen deposition — rationale for HBOT as a post-game recovery tool for elite athletes.

Cristiano Ronaldo and Gareth Bale

Both Cristiano Ronaldo and Gareth Bale have publicly used HBOT for injury recovery and performance maintenance. Ronaldo is reported to own a hyperbaric chamber, and Bale was frequently photographed at sessions during his injury rehabilitation periods. Michael Phelps has also cited HBOT as part of his Olympic recovery regimen.

Other Notable Athletes and Figures

NFL players across multiple franchises, NBA stars, UFC fighters, and numerous Hollywood figures have used HBOT — a trend amplified by the growing sports medicine evidence base and celebrity endorsements.

Cost & Economics

Typical Session Costs

HBOT session pricing varies substantially by facility type, geography, and pressure achieved:

Facility/Chamber Type Typical Cost Per Session
Soft-shell portable (mild, 1.3 ATA) — wellness spa $50–$150
Hard-shell, mid-pressure (1.5–2.0 ATA) — independent clinic $150–$300
Hard-shell, clinical grade (2.0–3.0 ATA) — hospital outpatient $250–$650+
Hospital inpatient billing $1,000–$2,500+
National average (per Undersea & Hyperbaric Medicine journal) ~$400/session (2025)

Source: hbotguide.com 2025 Cost Guide, projectwellbeing.co

Complete treatment courses of 20–40 sessions typically cost $4,000–$24,000 for out-of-pocket payers. Package discounts of 20–30% are commonly available.

Insurance-Covered vs. Cash-Pay Economics

For the 14–15 covered Medicare indications, patients pay approximately 20% of the Medicare-approved amount. Private insurance largely mirrors Medicare, requiring prior authorization and documentation of failed standard therapy (particularly for diabetic wounds). Off-label uses are almost never reimbursed, pushing patients to independent clinics with cash pricing.

A key economic argument for HBOT in wound care: preventing one lower-extremity amputation (which costs $30,000–$60,000 in surgical expenses alone, plus lifetime prosthetics and rehabilitation) can justify 30–40 HBOT sessions costing $10,000–$15,000.

Aviv Clinics Pricing Model

Aviv Clinics transparent pricing ranges from $18,214 (Performance Base, 8 weeks) to $48,596 (Enhancement Premium, 12 weeks with SPECT imaging, gait analysis, physical therapy, dietary coaching, and cognitive training). The signature program includes up to 60 HBOT sessions in 12 weeks (two-hour daily sessions, 5 days/week). These programs are entirely cash-pay; insurance coverage is not available for the wellness and cognitive enhancement indications.

Global Market Economics

The global HBOT market was valued at $3.98 billion in 2025, projected to reach $6.71 billion by 2034 (CAGR 5.96%), according to Precedence Research. North America holds 31% of market share. Wound healing is the dominant application segment. China and emerging markets are driving the fastest growth. The consumer wellness segment — driven by anti-aging, athletic recovery, and cognitive performance claims — is creating the fastest-growing new business model outside traditional wound care.

Research compiled May 2025. All facts cited to primary sources. FDA indications language cited from UHMS reproduction of FDA consumer release. Medicare indications cited directly from medicare.gov. UHMS history cited from the 15th Edition Indications manual front matter.

← Case Studies and Patient Stories  ·  Research Hub  ·  Sauna Therapy — Infrared, Finnish, and Steam →
Download full PDF ↓